Products

The integration of Stem Cell Technologies, Genomics and Bioinformatics allow Cellastra to be in an outstanding position of providing a wide array of products and services. Our Business Concept is to develop and commercialize innovative research technologies and therapeutics for multiple chronic diseases. Cellastra’s technology platform develops tools to engineer new hESCs and examines the genetic quality to facilitate development of stem cells therapeutics and drug discovery platforms.

Cellastra's unique collection of hESCs have been developed by our co-founder Dr. Outi Hovatta, MD, PhD, Professor, Karolinska University Hospital, Stockholm, Sweden. This inventory of superior quality stem cell lines-free of animal protein contaminations provide Cellastra a leading position of advantage in the field. This large inventory of human embryonic stem cell lines developed under strict, uniform GLP/GMP conditions allow us to develop Clinical Grade Drug Discovery Platforms with Clinical Grade Products.

Cellastra’s hESC lines, CellastraHSCTM lines are mainly intended for commercial companies under individually negotiated licenses for developmental applications, including drug discovery, toxicology, regenerative medicine and cancer therapeutics.

Cellastra’s hESC lines, CellastraHSC^TM are clonal, pluripotent cells. The research and developmental benefits of CellastraHSC^TM include:

* Derivation and cultivation free of animal proteins

* GLP/GMP grade production

* Cloned from good quality blastocysts obtained under EU’s strict ethical and regulatory requirements

* Pluripotent, undifferentiated with multiple applications and capable of multiple doublings without differentiating

* Genetically and epigenetically characterized

* Readily available inventory of multiple hESC lines for statistically significant data

* Clonal population with good experimental reproducibility

* Stem cell cultivation methods and human feeder cells also available

CellastraHSC^TMlines Applications for Drug Discovery Platforms in Biotech/Pharma Industries include:

1. Proprietary Clinical Grade Astrocytes Derived from Clinical Grade hESCs: Astrocytes work by signaling the tissue to repair in several ways, such as by suppressing scar tissue, rescuing motor pathway neurons in the brain, aligning damaged tissue at the injured site and support nerve fiber growth, e.g. in spinal cord injuries. The hESC-derived astrocytes have multiple applications for the treatment of spinal cord injuries, Parkinson’s, Multiple Sclerosis, Alzheimer’s, etc. Development of Pre-differentiated clonal stem cells of a particular lineage is a remarkable advent in technology for transplantations and pharmacological screenings.

2. Clinical Applications of Cellastra’s Genetic Portofolio CellastraGenie^TM : At the user end, for clinical applications in treatment of diseases like Diabetes, Leukemia, etc. Cellastra’s comprehensive Genetic Portofolio on the available hESCs provides information required for FDA approval, establish clonal population for transplantations, develop Biomarkers to establish pluripotent versus differentiated state of cells. This information allows for Managed, Regulated use of pluripotent cells.

3. Pharmacogenomics: Cellastra’s comprehensive Genetic Portofolio CellastraGenie^TM contains information on the large inventory of unique stem cell lines. CellastraGenieTM will be a valuable tool for a number of clinical trials, allowing for rapid data analysis and facilitating safe, effective design of clinical trials, focusing on Personalized Medicine.

4. Stem Cells in Cancer Therapy: Majority of anti-cancer agents and chemotherapy target adult tumor or cancer cells. The detection of cancer stem cells suggests that these newly formed, continually dividing cells possibly are not targeted by anti-cancer agents, resulting in reappearance of cancers. Therapeutic responses of stem cells can be different from those of adult tumor/cancer cells. hESCs serve as good model for testing various anti-cancer and anti-tumor agents in Drug Discovery Platforms.

5. Developing Animal Models with Human Neurons: Drug Discovery and Therapeutics Development for Neurodegenerative Diseases like Alzheimer’s and Huntington’s requires good animal models, which are currently lacking. Transplanting good quality, clonal Human ESCs in rodent brains can serve as an excellent model for testing new drugs and gene therapy strategies.

6. Drug or Growth Factors Delivery Vehicles: Stem Cells can be used as delivery vehicles, e.g. for growth factors like GDNF1 and neuropeptides for treatment of Parkinson’s disease and Alzheimer's respectively, especially in the mid-brain.

7. Stem Cell Transplantation: CellastraHSC^TM will be developed as the best resource for Stem Cell Transplantation therapeutic procedures.